182496-01-1

Basic information

• Product Name: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine
• Synonyms: N-Benzoyl-2'-O-methoxyethyl-5-O-dimethoxytrityl-5-methylcytidine;N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine;N-benzoyl-5'-O-DMTr-2'-O-(2-Methoxyethyl)-5-Methyl Cytidine;N4-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-O-(2-methoxyethyl)-5-methylcytidine;N-(1-((2R,3R,4R,5R)-5-((Bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxy-3-(2-methoxyethoxy)tetrahydrofuran-2-yl)-5-methyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide;N4-Benzoyl-5'-O-DMT-2'-O-(2-Methoxyethyl)-5-methylcytidine
• CAS NO: 182496-01-1
• Molecular Formula: C₄₁H₄₃N₃O₉
• Molecular Weight: 722
• Mol File: 182496-01-1.mol

Chemical Properties

• Appearance: /
• Density: 1.26
• PKA: 8.60±0.40(Predicted)
• CAS DataBase Reference: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine(182496-01-1)
• EPA Substance Registry System: N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine(182496-01-1)

Safety Data

• Hazardous Substances Data: 182496-01-1(Hazardous Substances Data)

Usage

Uses

Used in Synthetic Nucleic Acids Preparation:
N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine is used as a protected building block for the synthesis of synthetic nucleic acids. The protective groups on the cytidine molecule allow for controlled and selective reactions during the assembly of nucleic acid sequences, ensuring the integrity and stability of the final product. N-Benzoyl-5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-(2-methoxyethyl)-5-methylcytidine is particularly useful in the development of modified nucleic acids with enhanced properties, such as increased stability, improved binding affinity, or altered biological activity.

Upstream product

• 93-97-0 benzoic acid anhydride 
• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 256223-97-9 5'-O-(dimethoxytrityl)-3'-O-(2-methoxyethyl)5-methyl cytidine 
• 144-55-8 sodium hydrogencarbonate 
• 40615-35-8 4,4'-dimethoxytrityl alcohol 
• 340162-93-8 N⁴-benzoyl-2’-O-methoxyethyl-5-methylcytidine 
• 100-66-3 methoxybenzene 
• 98-07-7 Benzotrichlorid 
• 163759-50-0 5'-O-(4,4'-dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine 
• 163759-49-7 2'-O-(2-methoxyethyl)-5-methyluridine 
• 40615-36-9 4,4'-dimethoxytrityl chloride 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 

Downstream Products

• 163759-94-2 MOE 5-Me-C Amidite 
• 1536204-27-9 C₄₅H₄₇N₃O₁₂*C₆H₁₅N 
• 1536199-94-6 C₅₀H₅₉N₄O₁₀P 
• 1536203-21-0 C₃₈H₄₅N₃O₉ 
• 182496-00-0 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine 
• 340162-93-8 N⁴-benzoyl-2’-O-methoxyethyl-5-methylcytidine 

Relevant articles and documents

Copper(II)nitrate catalyzed regioselective protection of primary alcohols with 4,4′-dimethoxytrityl and 2,7-dimethyl-9-phenyl xanthen-9-yl groups in nucleosides and carbohydrates

Regioselective protection of primary hydroxyl group in nucleoside and carbohydrate analogs was accomplished using dimethoxytrityl alcohol (DMTr-OH) or dimethylpixyl alcohol (DMPx-OH) in presence of copper(II)nitrate as a Lewis acid catalyst. Excellent selectivity was observed for the protection of primary hydroxyl group over secondary while glycosidic bond remain unaffected. Utility of this methodology was further exemplified via DMTr- and DMPx-protection of alipahtic acyclic and cyclic diols.

Renewable amberlyst-15 catalyzed highly regioselective tritylation and deprotection of sugar-based diols

Amberlyst-15 catalyzed highly regioselective tritylation of sugar-based diols was achieved under mild condition using 4,4′-dimethoxytrityl alcohol (DMTrOH). Deprotection of the corresponding DMTr group was also established by the variation to protic solvent. Meanwhile, the heterogeneous catalyst Amberlyst-15 was recycled 3 times with satisfactory retention of catalytic activity and proved its potential application in industry.

EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided. Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Antisense modulation of CD40 ligand expression

Antisense compounds, compositions and methods are provided for modulating the expression of CD40 ligand. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding CD40 ligand. Methods of using these compounds for modulation of CD40 ligand expression and for treatment of diseases associated with expression of CD40 ligand are provided.

Antisense modulation of PTP1B expression

Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or delaying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The present invention is also directed to compositions and methods for improving insulin sensitivity in an animal or for preventing or delaying the onset of insulin resistance in an animal. Also provided are compositions and methods for treating or preventing a metabolic condition in an animal. The metabolic condition may be, e.g., diabetes or obesity.

Antisense modulation of wrn espression

Antisense compounds, compositions and methods are provided for modulating the expression of WRN. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding WRN. Methods of using these compounds for modulation of WRN expression and for treatment of diseases associated with expression of WRN are provided.

Antisense modulation of stearoyl-CoA desaturase expression

Antisense compounds, compositions and methods are provided for modulating the expression of stearoyl-CoA desaturase. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding stearoyl-CoA desaturase. Methods of using these compounds for modulation of stearoyl-CoA desaturase expression and for treatment of diseases associated with expression of stearoyl-CoA desaturase are provided.

Antisense modulation of connective tissue growth factor expression

Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of diseases associated with expression of connective tissue growth factor are provided.

Antisense modulation of interferon gamma receptor 2

Antisense compounds, compositions and methods are provided for modulating the expression of Interferon gamma receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Interferon gamma receptor 2. Methods of using these compounds for modulation of Interferon gamma receptor 2 expression and for treatment of diseases associated with expression of Interferon gamma receptor 2 are provided.

Antisense modulation of EIF2C1 expression

Antisense compounds, compositions and methods are provided for modulating the expression of EIF2C1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding EIF2C1. Methods of using these compounds for modulation of EIF2C1 expression and for treatment of diseases associated with expression of EIF2C1 are provided.